Search Results
Your search for early matches 10332 pages
Showing 2801 - 2850Can Consumption of Vitamin D Reduce the Risk of Early-Onset Colorectal Cancer?
Consuming higher amounts of vitamin D—mainly from dietary sources—may help protect against developing young-onset colorectal cancer or precancerous colon polyps, according to the first study to show such an association. These findings were published by Kim et al in the journal Gastroenterology. The ...
Gut Microbiome and Cancer
In recent years, the gut microbiome has garnered considerable attention as a scientific field, with far-reaching potential for clinical good. The trillions of microorganisms that inhabit the digestive tract form an incredibly complex community, which participates in countless interactions with its...
Retrospective Study Compares Characteristics of Early-Onset vs Average-Onset Colorectal Cancer
A large retrospective study has found that early-onset colorectal cancers are clinically and genomically indistinguishable from average-onset colorectal cancers. In addition, the study found that more aggressive treatment based solely on the patient’s age at diagnosis is neither necessary nor...
Simulation Model–Based Clinical Decision Tool for Predicting Benefit of Adjuvant Chemoendocrine vs Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
As reported in the Journal of Clinical Oncology, Jayasekera et al have developed a clinical decision tool called BTxChoice that can be used with or without the 21-gene recurrence score to estimate the potential benefit of adjuvant chemoendocrine vs endocrine therapy in women with node-negative,...
Meta-analysis of Outcomes With the Addition of Adjuvant Trastuzumab to Chemotherapy for HER2-Positive Breast Cancer
In a study conducted by the Early Breast Cancer Trialists’ Collaborative Group and reported in The Lancet Oncology by Bradley et al, an individual patient data meta-analysis of randomized trials has shown that the addition of adjuvant trastuzumab to chemotherapy reduces the risk of disease...
Tackling the Challenge of Pancreatic Cancer: New Approaches
Pancreatic cancer remains an incorrigible foe, but recent advances in genomic profiling and targeted drug development are slowly improving the outlook for patients, according to Eileen M. O’Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology and Section Head,...
S. Vincent Rajkumar, MD, on Multiple Myeloma: Defining Cure
S. Vincent Rajkumar, MD, of the Mayo Clinic, talks about how, in light of the fact that multiple myeloma has been turned into a chronic disease for many people, what it means to “cure” patients; the difference between curable and cured in multiple myeloma; and key studies he is involved in that...
Risk of Early Cardiac Toxicity With Posttransplantation Cyclophosphamide After HSCT
In a French single-center retrospective cohort study reported in JACC: CardioOncology, Duléry et al found that posttransplantation cyclophosphamide was associated with a significantly increased risk of early cardiac events among patients receiving allogeneic hematopoietic stem cell transplantation...
Conquer Cancer Announces 2021 Israel Cancer Research Fund Career Development Award
Conquer Cancer, the ASCO Foundation, is pleased to announce Shlomit Strulov Shachar, MD, of Tel Aviv Sourasky Medical Center, is the recipient of the 2021 Conquer Cancer–Israel Cancer Research Fund (ICRF) Career Development Award. Dr. Shachar’s proposed study, entitled “Identifying Molecular...
ASCO and Community Oncology Alliance Publish Standards for Oncology Medical Home Model
ASCO and the Community Oncology Alliance (COA) have published standards for the oncology medical home (OMH), a comprehensive system of care delivery that supports coordinated, efficient, accessible, and evidence-based care.1 The standards serve as a roadmap for practice...
Fred Hutchinson Cancer Research Center, Seattle Children’s, and UW Medicine Lay Groundwork for Cancer Partnership
Fred Hutchinson Cancer Research Center (Fred Hutch), University of Washington (UW) Medicine, Seattle Cancer Care Alliance (SCCA), and Seattle Children’s have announced plans to explore restructuring their longtime relationship to accelerate a shared mission of advancing diagnosis, treatment, and...
JAVELIN Head and Neck 100 Trial: When Failure Seems Fatal, Hope Is Not Lost
Data from KEYNOTE-048 showed that the combination of the checkpoint inhibitor pembrolizumab with platinum-containing therapy improved overall survival vs cetuximab plus chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).1 The findings provided hope...
Salvage and Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: What’s ‘Just Right’ for Our Patients?
In the storied English fable “Goldilocks and the Three Bears,” a child enters a home and tastes three bowls of porridge. She prefers a bowl that is not too cold and not too hot but one that has just the right temperature. This “Goldilocks principle” of “just the right amount” can be applied to the...
Mortality Risk With Adjuvant vs Early Salvage Radiotherapy in Men With Adverse Pathology at Radical Prostatectomy for Prostate Cancer
In a retrospective cohort study reported in the Journal of Clinical Oncology, Derya Tilki, MD, of Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf, Hamburg, and colleagues found that adjuvant radiotherapy was associated with reduced risk for all-cause mortality vs early...
NCCN Foundation Announces Awards for Rising Cancer Research Leaders
The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® have announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards Program. The honorees will receive up to $150,000 in funding in the course of 2 years to advance research on important issues in...
Expert Point of View: Nicole Chau, MD
ASCO discussant Nicole Chau, MD, Clinical Associate Professor at the University of British Columbia/BC Cancer in Vancouver, said the COSMIC-311 trial was “noteworthy for meeting its co-primary endpoint of progression-free survival (hazard ratio = 0.22) in this heavily pretreated patient...
Cabozantinib: Potential New Option for Treatment-Refractory Thyroid Cancer
The tyrosine kinase inhibitor cabozantinib appears to be an effective new option for treatment-refractory differentiated thyroid cancer, according to the phase III COSMIC-311 trial, which was stopped early for efficacy.1 COSMIC-311 is the first randomized placebo-controlled trial to evaluate the...
Expert Point of View: Melinda L. Telli, MD
The invited discussant of GeparNuevo,1 Melinda L. Telli, MD, Associate Professor of Medicine at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, welcomed the additional data...
Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial
In the phase II GeparNuevo trial, patients with early triple-negative breast cancer receiving the PD-L1 inhibitor durvalumab in addition to chemotherapy as neoadjuvant therapy saw improvements in long-term outcomes. The results were presented at the 2021 ASCO Annual Meeting by Sibylle Loibl, MD,...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
The ASCO Post invited Jacqueline C. Barrientos, MD, MS, Associate Professor of Medicine, CLL Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, to comment on the ALPINE findings presented at the European Hematology Association (EHA) Virtual...
Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer “next-generation ...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer...
Nationally Recognized Biostatistician Joins Rutgers to Focus on Cancer Research
The Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey have welcomed nationally recognized biostatistician Hao Liu, PhD. Dr. Liu will serve as Professor in the Department of Biostatistics and Epidemiology at Rutgers School of Public Health, Director of the Biostatistics...
From Istanbul to Orange County, an Oncologist’s Journey to a Leadership Role in Quality Care
Pelin Cinar, MD, MS, was born and reared in Istanbul, Turkey. “My father ran a small furniture business, and my mother was a homemaker. However, I had a distant cousin who was an obstetrician-gynecologist, but he did house calls and treated any number of health issues in the community. Early on, I ...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel gene therapies for resistant non-Hodgkin lymphomas (NHL), including...
A New Era of Hope for Patients With Triple-Negative Breast Cancer
Triple-negative breast cancer is a particularly devastating subtype of breast cancer, as it is often diagnosed in young women and is associated with an exceptionally poor prognosis. The “triple-negative” designation indicates that the three key features driving most breast cancers (estrogen...
Is Disease-Free Survival the Best Endpoint for Adjuvant Nivolumab in High-Risk, Muscle-Invasive Urothelial Carcinoma?
The role of adjuvant treatment for invasive, high-grade bladder cancer remains controversial and challenging. Sternberg et al reported a statistically significant progression-free survival benefit from adjuvant combination gemcitabine/cisplatin (GC) or MVAC (methotrexate, vinblastine, doxorubicin, ...
Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer
In a phase III trial reported in The New England Journal of Medicine, Michael Gnant, MD, and colleagues found no difference in disease-free survival with 2 vs 5 years of treatment with the aromatase inhibitor anastrozole in postmenopausal women with early hormone receptor (HR)-positive breast...
Lung Cancer Screening Rates Improved in 19 States Despite the COVID-19 Pandemic
A new population-based study showed that although national lung cancer screening rates decreased in some states, 19 states actually experienced significant improvements in screening rates despite the COVID-19 pandemic. Overall lung cancer screening rates remained low and unchanged, according to...
Use of Statins and Survival Outcomes Among Patients With Triple-Negative Breast Cancer
A study published by Nowakowska et al in the journal Cancer has found a significant association between the use of cholesterol-lowering statins and survival rates of patients with triple-negative breast cancer. Since statins are relatively inexpensive, easy to access, and produce minimal side...
Does Pain Affect the Employment and Financial Outcomes of Cancer Survivors?
In a study reported in the Journal of Clinical Oncology, Halpern et al found that cancer survivors with pain had worse employment and financial outcomes than did those reporting no pain. Study Details The study used data from 1,213 adult survivors identified from the 2016–2017 Medical Expenditure...
Tremelimumab, Durvalumab, or Both in Unresectable Hepatocellular Carcinoma
In a randomized expansion phase of a phase I/II study reported in the Journal of Clinical Oncology, Robin Kate Kelley, MD, and colleagues found that a novel regimen consisting of a single priming dose of tremelimumab in combination with durvalumab was associated with good outcomes in patients with...
Addition of Metformin to Chemoradiotherapy for Locally Advanced NSCLC
As reported in JAMA Oncology by Tsakiridis et al, the Canadian phase II OCOG-ALMERA trial, which was closed early due to slow accrual, showed that the addition of metformin to chemoradiation therapy was associated with worse outcomes in patients with unresected locally advanced non–small cell lung ...
Expert Point of View: Giuseppe Curigliano, MD, PhD
Invited discussant Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at the University of Milan, Italy, and Head of the Division of Early Drug Development at the European Institute of Oncology, said the “clear” findings of KEYNOTE-5221 are “practice-changing.” However, the...
KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer
The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer.1 This is the first large, randomized, phase III...
Surbhi Sidana, MD, Comments on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said CAR T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For this population of triple...
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma
For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...
Study Shows Cancer Trials Adapted Rapidly During the COVID-19 Pandemic
Cancer clinical trial research rapidly adapted to the circumstances of enrolling and treating patients in clinical trials during the COVID-19 pandemic, according to findings from a study of enrollment during 2020 and early 2021 published by Joseph M. Unger, PhD, and colleagues in JAMA Network ...
Meta-analysis Identifies Genetic Markers for Inherited Testicular Cancer
A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited testicular germ cell tumors—a 40% increase in the number of regions known to be associated with the cancer. The new findings, published by Pluta et al in Nature Communications, could help...
Expert Point of View: Lisa Carey, MD
NEOTALA’s invited discussant, Lisa Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, saw the findings as part of a bigger trend toward reducing the use of...
Single-Agent Talazoparib Shows Activity in the Neoadjuvant Treatment of Triple-Negative Breast Cancer
For the neoadjuvant treatment of triple-negative breast cancer, the oral poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib yielded promising pathologic complete response rates in the phase II single-arm NEOTALA trial presented at the 2021 ASCO Annual Meeting.1 Preoperative chemotherapy is...
How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment
Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...
Can Treatment With Thiopurines Induce Mutations That May Lead to Pediatric Leukemia Relapse?
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, a research team has shown how thiopurines may lead to mutations that set patients up for disease relapse. These findings were published by Yang et al in Nature Cancer. The research...
Expert Point of View: Evandro de Azambuja, MD, PhD
“KAITLIN didnot meet its primary endpoint, either in the intent-to-treat or node-positive population,1 but in context with the APHINITY trial [1 year of adjuvant pertuzumab/trastuzumab plus chemotherapy],2 whose outcomes were similar at 3 years, you can appreciate that both arms did extremely...
KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy for HER2-Positive Early Breast Cancer
In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease–free survival in the node-positive or intent-to-treat population of women with high-risk, HER2-positive early breast...
Cancer vs Non–Cancer-Related Deaths Among Older Patients Selected for Surgical Treatment
In a Canadian population-based cohort study reported in JAMA Surgery, Chesney et al found that the 5-year rate of cancer-related deaths exceeded that of non–cancer-related deaths among patients aged 70 or older undergoing surgery for cancer. Study Details The study used data from ICES (formerly...
FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage Triple-Negative Breast Cancer
On July 26, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. The FDA also...
HR-Positive/HER2-Negative Early Breast Cancer
In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the management of hormone receptor (HR)-positive, HER2-negative early breast cancer. The faculty present the case of a 54-year-old perimenopausal Black woman who has been diagnosed with high-grade T3N1 left...
